Clinical trials have been conducted to determine the effectiveness of CXCR5-expressing anti-EGFR CAR-T cells in patients with advanced EGFR positive NSCLC (NCT05060796, NCT04153799). This evidence concerns the gene EGFR and non-small cell lung carcinoma.